Epilepsy News

PHILADELPHIA — In older adults, the presence of white and gray matter abnormalities on MRI is linked to greater risk for late-onset epilepsy, according to a poster presentation.

PHILADELPHIA — Among a small cohort of women with epilepsy who were attempting to conceive a child, no associations were found between pregnancy and change in catamenial seizure reduction, according to a poster presentation.

An umbrella review published in The BMJ provided a breakdown of the associations between cannabis and health outcomes, highlighting the uncertain potential for clinical use.

A global clinical-stage biopharmaceutical company announced positive biomarker data from its exploratory phase 1 electroencephalogram biomarker study of novel and selective Kv7.2/Kv7.3 activator BHV-700 to treat epilepsy.

Stoke Therapeutics Inc. has announced new positive data regarding its proprietary antisense oligonucleotide therapeutic to treat Dravet syndrome.

The FDA has granted 510(k) clearance to a medical device company for its software that diagnoses electrographic status epilepticus in adults.

NYU Langone Hospitals was named the top hospital in the United States for neurology and neurosurgery by the U.S. News & World Report’s annual Best Hospitals survey.

A biotechnology company has announced positive safety and efficacy data from two ongoing phase 1/2a studies as well as an open-label extension study of STK-001 to treat younger individuals with Dravet syndrome.

Over the past few years, products based on CBD and medical marijuana have become widely available and accepted as treatments for various ailments.

BOSTON — Two studies presented at the American Academy of Neurology meeting showed treatment with Aptiom improved quality of life scores and reduced frequency in patients with focal seizures.